text
"['\nIX. 계열회사 등에 관한 사항\n1. 계열회사의 현황가. 기업집단의 명칭 : 녹십자나. 기업집단 소속회사의 현황\xa0\n구분\n회사수\n회사명\n사업의 내용\n소재지\n사업자등록번호\n상장사\n6\n㈜녹십자홀딩스\n임대, 서비스업\n대한민국\n135-81-05009\n㈜녹십자\n의약품제조및판매\n대한민국\n303-81-17108\n㈜녹십자셀\n의약품제조및판매\n대한민국\n214-86-11207\n㈜녹십자엠에스\n의약품제조및판매\n대한민국\n135-81-67475\n㈜녹십자랩셀\n혈액진단업\n대한민국\n142-81-37741\n㈜녹십자웰빙\n의약품제조\n대한민국\n135-81-72584\n비상장사\n26\n㈜녹십자이엠\n기계설비공사\n대한민국\n135-81-44619\n㈜녹십자헬스케어\n의료서비스\n대한민국\n120-86-55953\n농업회사법인인백팜㈜\n축산업\n대한민국\n408-81-76042\n㈜녹십자지놈\n유전자 분석\n대한민국\n142-81-61687\nCurevo, Inc.\n의약품 연구\n미국\n82-3739400\n㈜지씨웰페어\n기타 서비스업\n대한민국\n142-81-36214\n㈜녹십자메디스\n의료기기\n대한민국\n410-81-93457\n㈜아진디앤엠\n부동산 임대업\n대한민국\n102-87-00194\n㈜지씨씨엘\n임상분석 검체분석\n대한민국\n253-88-01348\n글로벌바이오인프라제이호 사모투자합자회사\n투자조합\n대한민국\n527-87-01408\nGC Lymphotec lnc.\n세포치료제제조및판매\n일본\n0106-01-036063\n녹십자(중국) 생물제품유한공사(GC China)\n의약품제조및판매\n중국\n9134040061037999005\n안휘거린커약품판매유한공사\n의약품 판매\n중국\n913404005957110384(1-1)\nTaoJiang Green Cross PlasmaCenter Co.,Ltd.\n의약품 제조\n중국\n91430922070571693J\nShouXian Green Cross PlasmaCenter Co.,Ltd.\n의약품 제조\n중국\n91340422677573185W\nNingGuo Green Cross PlasmaCenter Co.,Ltd.\n의약품 제조\n중국\n913418817981152286(1-1)\nDangShan Green Cross PlasmaCenter Co.,Ltd.\n의약품 제조\n중국\n913413216789804122(1-1)\nGreen Cross America,Inc.\n의료업\n미국\n80-0510204\nGreen Cross HK Holdings Limited.\n기타 서비스\n홍콩\n52553241-000-07-15-A\nGreen Cross North America Inc.\n기타 서비스\n캐나다\n818724577 RC0001\nGC MOGAM, Inc.\n의약품 판매\n미국\n81-3744746\nGreen Cross BioTherapeutics Inc.\n의약품제조및판매\n캐나다\n827385774 RC0001\nGC Labtech, Inc.\n기타 보건업\n미국\n81-3707136\nGC DO BRASIL PARTICIPACOES LTDA\xa0\n서비스\n브라질\n30.175.318/0001-74\nGC Meizhou Biological Product Co.,Ltd\n의약품 제조\n중국\n91441400MA4W7BMQ46\nArtiva Biotherapeutics, Inc.\n세포치료제 개발\n미국\n86-3614316\n다. 계열회사간 출자 현황\r\n[2019.12.31 현재]\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0(단위 : %)\n\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0 투자회사피투자회사\n㈜녹십자홀딩스\n㈜녹십자\n㈜녹십자엠에스\n㈜녹십자랩셀\n㈜녹십자이엠\n㈜녹십자셀\n녹십자지놈\n녹십자(중국)생물제품유한공사(GC China)\nGreen Cross HKHoldings Limited.\nGreen CrossNorth America Inc\nGreen Cross BioTherapeutics Inc\n㈜녹십자홀딩스\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n㈜녹십자\n50.06\n\u3000\n\u3000\n\u3000\n0.16\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n㈜녹십자셀\n4.86\n24.17\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n㈜녹십자엠에스\n\u3000\n41.51\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n㈜녹십자이엠\n100.00\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n㈜녹십자헬스케어\n69.01\n0.58\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n㈜녹십자웰빙(*1)\n12.39\n22.08\n0.06\n\u3000\n\u3000\n0.23\n0.11\n\u3000\n\u3000\n\u3000\n\u3000\n농업회사법인 인백팜㈜\n\u3000\n92.55\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n㈜녹십자랩셀\n9.29\n38.66\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n㈜녹십자지놈\n\u300010.36\n33.26\n0.07\n\u3000\n\u3000\n0.29\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n㈜지씨웰페어\n70.00\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n㈜녹십자메디스\n\u3000\n36.85\n61.41\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n㈜지씨씨엘\n\u3000\n\u3000\n\u3000\n67.02\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\nCurevo, Inc.\xa0\n\u3000\n81.36\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n녹십자(중국) 생물제품유한공사(GC China)\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n100.00\n\u3000\n\u3000\n안휘거린커약품판매유한공사\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n100.00\n\u3000\n\u3000\n\u3000\nTaoJiang Green Cross PlasmaCenter Co.,Ltd.\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n100.00\n\u3000\n\u3000\n\u3000\nShouXian Green Cross PlasmaCenter Co.,Ltd.\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n100.00\n\u3000\n\u3000\n\u3000\nNingGuo Green Cross PlasmaCenter Co.,Ltd.\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n100.00\n\u3000\n\u3000\n\u3000\nDangShan Green Cross Plasma Center Co.,Ltd.\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n100.00\n\u3000\n\u3000\n\u3000\nGreen Cross America,Inc.\n\u3000\n25.93\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n74.07\nGC MOGAM, Inc.\xa0\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n100.00\nGreen Cross HK Holdings Limited.\n84.78\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\nGreen Cross North America Inc\n53.15\n46.85\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\nGreen Cross Bio Therapeutics Inc\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n53.40\n\u3000\nGC Labtech, Inc.\n100.00\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\nGC Meizhou Biological Product Co.,Ltd\n100.00\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\nGC DO BRASIL PARTICIPACOES LTDA\xa0\n\u3000\n99.99\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\nGC Lymphotec lnc.\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n83.27\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\nArtiva Biotherapeutics, Inc.\n51.00\n\u3000\n\u3000\n34.00\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n글로벌바이오인프라제이호 사모투자합자회사\n49.51\n\u3000\n\u3000\n49.50\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000\n라. 등기임원의 겸직 현황 : 해당사항 없음\n2. 타법인출자 현황\n(기준일 :\xa0\n2019년 12월 31일\n)\n(단위 : 백만원, 주, %)\n법인명\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n㈜녹십자엠에스(*1)(상장)\n2010년 11월 25일\n경영참가\n6,837\n4,024,708\n42.1%\n7,120\n4,740,996\n21,263\n-\n8,765,704\n41.5%\n28,383\n85,901\n-16,675\n㈜녹십자셀(상장)(*2)\n2012년 08월 16일\n경영참가\n15,000\n2,927,055\n24.7%\n25,024\n-\n-\n-\n2,927,055\n24.2%\n25,024\n151,787\n10,728\n㈜녹십자랩셀(상장)\n2011년 06월 22일\n경영참가\n100\n4,080,000\n38.7%\n2,040\n-\n-\n-\n4,080,000\n38.7%\n2,040\n64,917\n1,691\n농업회사법인인백팜㈜(비상장)\n2013년 12월 31일\n경영참가\n7,115\n993,690\n92.5%\n7,115\n-\n-\n-\n993,690\n92.5%\n7,115\n18,606\n685\n㈜녹십자웰빙(상장)(*3)\n2009년 04월 24일\n경영참가\n9,792\n3,920,250\n29.8%\n11,150\n-\n-\n-\n3,920,250\n22.1%\n11,150\n106,716\n5,699\n㈜녹십자지놈(비상장)(*4)\n2013년 08월 01일\n경영참가\n2,031\n4,671,500\n51.9%\n2,336\n-15,000\n-8\n-\n4,656,500\n33.3%\n2,328\n14,010\n233\nGCAM(비상장)\n2009년 12월 17일\n경영참가\n1,785\n600,000\n25.9%\n6,714\n-\n-\n-\n600,000\n25.9%\n6,714\n53,220\n-8,022\nGCNA(비상장)\n2014년 04월 22일\n경영참가\n474\n51,544,201\n46.8%\n50,566\n-\n-\n-\n51,544,201\n46.8%\n50,566\n110,838\n-\n㈜메디진바이오(비상장)(*5)\n2010년 03월 31일\n경영참가\n200\n10,000\n50.0%\n455\n-10,000\n-455\n-\n10,000\n50.0%\n-\n-\n-\n㈜녹십자메디스(비상장)\n2015년 01월 27일\n경영참가\n3,873\n11,559,554\n36.8%\n1,903\n-\n-\n-543\n11,559,554\n36.8%\n1,360\n6,108\n-325\n한일홀딩스㈜(상장)\n2004년 05월 15일\n단순투자\n5,620\n45,065\n1.3%\n2,347\n-\n-\n-369\n45,065\n0.8%\n1,978\n1,286,350\n-61,476\n한일시멘트㈜(상장)\n2004년 05월 15일\n단순투자\n-\n54,934\n1.3%\n6,455\n-\n-\n-1,324\n54,934\n1.3%\n5,131\n1,383,564\n40,505\nArgos(상장) (*6)\n2013년 08월 02일\n단순투자\n4,514\n511,901\n3.3%\n1\n-486,306\n-\n-1\n25,595\n3.3%\n-\n12,187\n-14,964\nMacroGenics(상장)\n2011년 01월 19일\n단순투자\n2,268\n163,366\n0.5%\n2,320\n-\n-\n-481\n145,990\n0.5%\n1,839\n397,373\n-139,518\n㈜파멥신(상장)\n2009년 08월 26일\n단순투자\n104\n281,244\n5.7%\n22,500\n-\n-\n-11,630\n281,244\n5.7%\n10,870\n161,818\n-9,690\n유바이오로직스(상장)\n2013년 05월 29일\n단순투자\n1,200\n2,140,000\n7.9%\n12,840\n-500,000\n-3,000\n3,116\n1,640,000\n6.1%\n12,956\n92,765\n-882\n㈜연합뉴스티브이(비상장)\n2011년 02월 10일\n단순투자\n500\n100,000\n0.8%\n162\n-\n-\n-\n100,000\n0.8%\n162\n46,657\n5,486\n㈜조선방송(비상장)\n2011년 01월 28일\n단순투자\n2,000\n400,000\n0.7%\n1,605\n-\n-\n-\n400,000\n0.7%\n1,605\n270,716\n3,276\n㈜채널에이(비상장)\n2011년 02월 18일\n단순투자\n2,000\n400,000\n0.5%\n1,282\n-\n-\n-\n400,000\n0.5%\n1,282\n294,052\n-7,528\n㈜매일방송(비상장)\n2011년 03월 04일\n단순투자\n2,000\n266,667\n0.5%\n1,337\n-\n-\n-\n266,667\n0.5%\n1,337\n435,586\n-781\nCurevo, Inc.(비상장)\n2018년 02월 26일\n경영참가\n5,537\n5,000,000\n81.4%\n5,357\n-\n-\n-\n5,000,000\n81.4%\n5,357\n5,670\n-4,525\nCurevo, Inc.(비상장)(*7)\n2019년 07월 30일\n경영참가\n5,880\n-\n-\n-\n-\n5,880\n-91\n-\n-\n5,789\n5,670\n-4,525\nGC DO BRASIL (비상장)(*8)\n2018년 05월 04일\n경영참가\n534\n500,000\n99.9%\n534\n500,000\n591\n-\n1,000,000\n99.9%\n1,125\n817\n-128\n다이노나(상장)\n2000년 08월 25일\n단순투자\n500\n83,330\n0.5%\n-\n-\n-\n433\n83,330\n0.5%\n433\n25,872\n-7,556\n노바자임(비상장)\n2019년 11월 29일\n단순투자\n2,005\n-\n-\n-\n344\n2,005\n-\n344\n2.8%\n2,005\n1,696\n-589\n합 계\n-\n-\n171,163\n-\n26,276\n-10,890\n-\n-\n186,549\n-\n-\n(*) 출자비율이 5%를 초과하거나 장부가액이 1억원을 초과하는 타법인 출자현황을기재하였습니다. 또한, 최근사업연도 자료의 확보가 곤란한 비상장사(계열사 제외)는 확보할 수 있는 가장 최근의 재무현황을 기재하였습니다.(*1) 상기건은 유상증자 참여 건 입니다.\n(*2) (주)녹십자셀이 발행한 전환사채 일부의 전환권이 행사됨에 따라 지분율이 변동하였습니다.(*3) (주)녹십자웰빙이 IPO를 진행함에 따라 지분율이 변동하였습니다.(*4) (주)녹십자지놈 일부 주식매각 및 유상증자를 진행함에 따라 지분율이 변동하였습니다.(*5) (주)메디진바이오는 전량 매각하였습니다.(*6) Argos는 주식 병합으로 인한 주식 수 변동이 이루어졌습니다.(*7) Curevo 전환사채 투자 건 입니다.(*8) GC DO BRASIL 유상증자 참여 건 입니다.\n']"
